Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears

Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears

Chronic hepatitis increases the risk of hepatocellular carcinoma (HCC). To test whether circulating proteins reflect hepatic carcinogenesis, sera from patients and controls were albumin depleted, enriched for glycoproteins, digested with trypsin, and subjected to reverse phase chromatography and tan...

Full description

Bibliographic Details
Main Authors: James N. Riggins, William Corey, Alfred N. Fonteh, Michael G. Harrington
Format: Article
Language:English
Published: Hindawi Limited 2010-01-01
Series:Disease Markers
Online Access:http://dx.doi.org/10.3233/DMA-2010-0692
id doaj-7665801606cb467a9aa0063d0e70eee4
record_format Article
spelling doaj-7665801606cb467a9aa0063d0e70eee42020-11-24T22:41:32ZengHindawi LimitedDisease Markers0278-02401875-86302010-01-0128312513510.3233/DMA-2010-0692Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer AppearsJames N. Riggins0William Corey1Alfred N. Fonteh2Michael G. Harrington3Molecular Neurology Program, Huntington Medical Research Institutes, Pasadena, CA, USAHMRI Liver Center, Pasadena, CA, USAMolecular Neurology Program, Huntington Medical Research Institutes, Pasadena, CA, USAMolecular Neurology Program, Huntington Medical Research Institutes, Pasadena, CA, USAChronic hepatitis increases the risk of hepatocellular carcinoma (HCC). To test whether circulating proteins reflect hepatic carcinogenesis, sera from patients and controls were albumin depleted, enriched for glycoproteins, digested with trypsin, and subjected to reverse phase chromatography and tandem mass spectrometry. Alpha-fetoprotein enhancer binding protein (AFPebp), a tumor suppressor, was repeatedly identified in sera from chronic HBV hepatitis patients. We independently identified and quantified AFPebp with a deuterated, phenylisocyanate-labeled synthetic peptide standard. Elevated AFPebp levels in sera from chronic HBV hepatitis patients decreased as cancer developed. These data suggest that rising AFPebp levels in chronic HBV hepatitis may be protective, while falling levels may contribute to HCC development.http://dx.doi.org/10.3233/DMA-2010-0692
collection DOAJ
language English
format Article
sources DOAJ
author James N. Riggins
William Corey
Alfred N. Fonteh
Michael G. Harrington
spellingShingle James N. Riggins
William Corey
Alfred N. Fonteh
Michael G. Harrington
Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears
Disease Markers
author_facet James N. Riggins
William Corey
Alfred N. Fonteh
Michael G. Harrington
author_sort James N. Riggins
title Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears
title_short Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears
title_full Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears
title_fullStr Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears
title_full_unstemmed Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears
title_sort blood serum alpha fetoprotein enhancer binding protein, a tumor suppressor, decreases in chronic hbv hepatitis patients as hepatocellular cancer appears
publisher Hindawi Limited
series Disease Markers
issn 0278-0240
1875-8630
publishDate 2010-01-01
description Chronic hepatitis increases the risk of hepatocellular carcinoma (HCC). To test whether circulating proteins reflect hepatic carcinogenesis, sera from patients and controls were albumin depleted, enriched for glycoproteins, digested with trypsin, and subjected to reverse phase chromatography and tandem mass spectrometry. Alpha-fetoprotein enhancer binding protein (AFPebp), a tumor suppressor, was repeatedly identified in sera from chronic HBV hepatitis patients. We independently identified and quantified AFPebp with a deuterated, phenylisocyanate-labeled synthetic peptide standard. Elevated AFPebp levels in sera from chronic HBV hepatitis patients decreased as cancer developed. These data suggest that rising AFPebp levels in chronic HBV hepatitis may be protective, while falling levels may contribute to HCC development.
url http://dx.doi.org/10.3233/DMA-2010-0692
work_keys_str_mv AT jamesnriggins bloodserumalphafetoproteinenhancerbindingproteinatumorsuppressordecreasesinchronichbvhepatitispatientsashepatocellularcancerappears
AT williamcorey bloodserumalphafetoproteinenhancerbindingproteinatumorsuppressordecreasesinchronichbvhepatitispatientsashepatocellularcancerappears
AT alfrednfonteh bloodserumalphafetoproteinenhancerbindingproteinatumorsuppressordecreasesinchronichbvhepatitispatientsashepatocellularcancerappears
AT michaelgharrington bloodserumalphafetoproteinenhancerbindingproteinatumorsuppressordecreasesinchronichbvhepatitispatientsashepatocellularcancerappears
_version_ 1725702011940241408

Similar Items